Reprint of: B Cells in Chronic Graft-versus-Host Disease

Stefanie Sarantopoulos; Bruce R. Blazar; Corey Cutler; Jerome Ritz

doi:10.1016/j.bbmt.2014.12.033

Reprint of: B Cells in Chronic Graft-versus-Host Disease

Stefanie Sarantopoulos, Bruce R. Blazar, Corey Cutler, Jerome Ritz

Administration (TMED)

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Chronic graft-versus-host disease (cGVHD) continues to be a common complication of allogeneic hematopoietic stem cell transplantation. Unlike acute graft-versus-host disease, which is mediated almost entirely by donor T cells, the immune pathology of cGVHD is more complex and donor B cells have also been found to play an important role. Recent studies from several laboratories have enhanced our understanding ofhow donor B cells contribute to this clinical syndrome and this has led to new therapeutic opportunities. Here, Dr Sarantopoulos reviews some of the important mechanisms responsible for persistent B cell activationand loss of B cell tolerance in patients with cGVHD. Dr Blazar describes recent studies in preclinical models that have identified novel B cell-directed agents that may be effective for prevention or treatment ofcGVHD. Some B cell-directed therapies have already been tested in patients with cGVHD and Dr Cutler reviews the results of these studies documenting the potential efficacy of this approach. Supported by mechanistic studies in patients and preclinical models, new B cell-directed therapies for cGVHD will now be evaluated in clinical trials.

Original language	English (US)
Pages (from-to)	S11-S18
Journal	Biology of Blood and Marrow Transplantation
Volume	21
Issue number	2
DOIs	https://doi.org/10.1016/j.bbmt.2014.12.033
State	Published - Feb 1 2015

Bibliographical note

Funding Information:
The authors thank Jing Du, Katelyn Goodman, and Drs Ryan Flynn, Jay Bradner, Jun Qi, Ari Melnick, Raphael Clynes, Alexandra Zanin-Zhorov, Jason Dubovsky, John Byrd, and Lawrence Elias for performing experiments, providing reagents and/or helpful discussions. We thank Rigel Pharmaceuticals for providing fostamatinib, Kadmon Pharmaceuticals for KD025, and Pharmacyclics for providing ibrutinib for laboratory studies. Studies described in this review were supported by NIH grants CA142106 , K08HL107756 , and AI056299 , DOD grant CA100254 , Kadmon Pharmaceuticals Inc and a translational grant from the Leukemia and Lymphoma Society of America ( LLS Grant 6458-15 ).

Publisher Copyright:
© 2015.

Keywords

B cell
Chronic graft-versus-host disease
Stem cell transplantation

Publisher link

10.1016/j.bbmt.2014.12.033

Find It

Find It at U of M Libraries

Cite this

@article{537fe2adbb1e40a2be3b0c5e1665348c,

title = "Reprint of: B Cells in Chronic Graft-versus-Host Disease",

abstract = "Chronic graft-versus-host disease (cGVHD) continues to be a common complication of allogeneic hematopoietic stem cell transplantation. Unlike acute graft-versus-host disease, which is mediated almost entirely by donor T cells, the immune pathology of cGVHD is more complex and donor B cells have also been found to play an important role. Recent studies from several laboratories have enhanced our understanding ofhow donor B cells contribute to this clinical syndrome and this has led to new therapeutic opportunities. Here, Dr Sarantopoulos reviews some of the important mechanisms responsible for persistent B cell activationand loss of B cell tolerance in patients with cGVHD. Dr Blazar describes recent studies in preclinical models that have identified novel B cell-directed agents that may be effective for prevention or treatment ofcGVHD. Some B cell-directed therapies have already been tested in patients with cGVHD and Dr Cutler reviews the results of these studies documenting the potential efficacy of this approach. Supported by mechanistic studies in patients and preclinical models, new B cell-directed therapies for cGVHD will now be evaluated in clinical trials.",

keywords = "B cell, Chronic graft-versus-host disease, Stem cell transplantation",

author = "Stefanie Sarantopoulos and Blazar, {Bruce R.} and Corey Cutler and Jerome Ritz",

note = "Funding Information: The authors thank Jing Du, Katelyn Goodman, and Drs Ryan Flynn, Jay Bradner, Jun Qi, Ari Melnick, Raphael Clynes, Alexandra Zanin-Zhorov, Jason Dubovsky, John Byrd, and Lawrence Elias for performing experiments, providing reagents and/or helpful discussions. We thank Rigel Pharmaceuticals for providing fostamatinib, Kadmon Pharmaceuticals for KD025, and Pharmacyclics for providing ibrutinib for laboratory studies. Studies described in this review were supported by NIH grants CA142106 , K08HL107756 , and AI056299 , DOD grant CA100254 , Kadmon Pharmaceuticals Inc and a translational grant from the Leukemia and Lymphoma Society of America ( LLS Grant 6458-15 ). Publisher Copyright: {\textcopyright} 2015.",

year = "2015",

month = feb,

day = "1",

doi = "10.1016/j.bbmt.2014.12.033",

language = "English (US)",

volume = "21",

pages = "S11--S18",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Reprint of

T2 - B Cells in Chronic Graft-versus-Host Disease

AU - Sarantopoulos, Stefanie

AU - Blazar, Bruce R.

AU - Cutler, Corey

AU - Ritz, Jerome

N1 - Funding Information: The authors thank Jing Du, Katelyn Goodman, and Drs Ryan Flynn, Jay Bradner, Jun Qi, Ari Melnick, Raphael Clynes, Alexandra Zanin-Zhorov, Jason Dubovsky, John Byrd, and Lawrence Elias for performing experiments, providing reagents and/or helpful discussions. We thank Rigel Pharmaceuticals for providing fostamatinib, Kadmon Pharmaceuticals for KD025, and Pharmacyclics for providing ibrutinib for laboratory studies. Studies described in this review were supported by NIH grants CA142106 , K08HL107756 , and AI056299 , DOD grant CA100254 , Kadmon Pharmaceuticals Inc and a translational grant from the Leukemia and Lymphoma Society of America ( LLS Grant 6458-15 ). Publisher Copyright: © 2015.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Chronic graft-versus-host disease (cGVHD) continues to be a common complication of allogeneic hematopoietic stem cell transplantation. Unlike acute graft-versus-host disease, which is mediated almost entirely by donor T cells, the immune pathology of cGVHD is more complex and donor B cells have also been found to play an important role. Recent studies from several laboratories have enhanced our understanding ofhow donor B cells contribute to this clinical syndrome and this has led to new therapeutic opportunities. Here, Dr Sarantopoulos reviews some of the important mechanisms responsible for persistent B cell activationand loss of B cell tolerance in patients with cGVHD. Dr Blazar describes recent studies in preclinical models that have identified novel B cell-directed agents that may be effective for prevention or treatment ofcGVHD. Some B cell-directed therapies have already been tested in patients with cGVHD and Dr Cutler reviews the results of these studies documenting the potential efficacy of this approach. Supported by mechanistic studies in patients and preclinical models, new B cell-directed therapies for cGVHD will now be evaluated in clinical trials.

AB - Chronic graft-versus-host disease (cGVHD) continues to be a common complication of allogeneic hematopoietic stem cell transplantation. Unlike acute graft-versus-host disease, which is mediated almost entirely by donor T cells, the immune pathology of cGVHD is more complex and donor B cells have also been found to play an important role. Recent studies from several laboratories have enhanced our understanding ofhow donor B cells contribute to this clinical syndrome and this has led to new therapeutic opportunities. Here, Dr Sarantopoulos reviews some of the important mechanisms responsible for persistent B cell activationand loss of B cell tolerance in patients with cGVHD. Dr Blazar describes recent studies in preclinical models that have identified novel B cell-directed agents that may be effective for prevention or treatment ofcGVHD. Some B cell-directed therapies have already been tested in patients with cGVHD and Dr Cutler reviews the results of these studies documenting the potential efficacy of this approach. Supported by mechanistic studies in patients and preclinical models, new B cell-directed therapies for cGVHD will now be evaluated in clinical trials.

KW - B cell

KW - Chronic graft-versus-host disease

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84921458497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921458497&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.12.033

DO - 10.1016/j.bbmt.2014.12.033

M3 - Review article

C2 - 25620647

AN - SCOPUS:84921458497

SN - 1083-8791

VL - 21

SP - S11-S18

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 2

ER -

Reprint of: B Cells in Chronic Graft-versus-Host Disease

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this